VERAXA Biotech shows tumor regression in first in‑vivo BiTAC‑ADC proof‑of‑concept
VERAXA Biotech AG presented pre‑clinical data at the World ADC Congress showing that a single 3 mg/kg dose of its BiTAC‑ADC platform caused strong tumor regression in a xenograft breast‑cancer model. The study reported no decrease in body weight, indicating a differentiated safety profile. Company executives said the results validate the platform and support its partnering strategy for safer solid‑tumor therapies.
Why it matters
The company says the data demonstrate a key platform milestone that could accelerate collaborations and de‑risk future clinical development. Investors may view the validation as a catalyst for partnership talks and pipeline advancement.
Key facts
- 1The in‑vivo study used a single dose of 3 mg/kg of BiTAC‑ADC in a xenograft breast‑cancer model. finanznachrichten.de
- 2The treatment produced strong tumor regression compared with control ADCs. finanznachrichten.de
- 3No decrease in body weight was observed in the BiTAC‑ADC arm. finanznachrichten.de
- 4Results were presented at the 17th World ADC Congress in San Diego on October 13 2026. finanznachrichten.de
- 5Company officials highlighted the safety benefits and potential for partnering on the platform. finanznachrichten.de
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.